A detailed history of Daiwa Securities Group Inc. transactions in Lyell Immunopharma, Inc. stock. As of the latest transaction made, Daiwa Securities Group Inc. holds 917 shares of LYEL stock, worth $1,008. This represents 0.0% of its overall portfolio holdings.

Number of Shares
917
Previous 917 -0.0%
Holding current value
$1,008
Previous $1,000 -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

2 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 09, 2022

BUY
$3.68 - $6.8 $791 - $1,462
215 Added 30.63%
917 $6,000
Q4 2021

Feb 03, 2022

BUY
$7.13 - $15.19 $5,005 - $10,663
702 New
702 $5,000

Others Institutions Holding LYEL

About Lyell Immunopharma, Inc.


  • Ticker LYEL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 247,824,992
  • Market Cap $273M
  • Description
  • Lyell Immunopharma, Inc., a T cell reprogramming company, engages in developing T cell therapies for patients with solid tumors. The company develops therapies using technology platforms, such as Gen-R, an ex vivo genetic reprogramming technology to overcome T cell exhaustion; and Epi-R, an ex vivo epigenetic reprogramming technology to generate...
More about LYEL
Track This Portfolio

Track Daiwa Securities Group Inc. Portfolio

Follow Daiwa Securities Group Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Daiwa Securities Group Inc., based on Form 13F filings with the SEC.

News

Stay updated on Daiwa Securities Group Inc. with notifications on news.